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a bs t r ac t
BACKGROUND

Despite the high rate of sudden death after myocardial infarction among patients
with a low ejection fraction, implantable cardioverter–defibrillators are contraindicated until 40 to 90 days after myocardial infarction. Whether a wearable cardioverter–defibrillator would reduce the incidence of sudden death during this high-risk
period is unclear.
METHODS

We randomly assigned (in a 2:1 ratio) patients with acute myocardial infarction and
an ejection fraction of 35% or less to receive a wearable cardioverter–defibrillator plus
guideline-directed therapy (the device group) or to receive only guideline-directed
therapy (the control group). The primary outcome was the composite of sudden death
or death from ventricular tachyarrhythmia at 90 days (arrhythmic death). Secondary
outcomes included death from any cause and nonarrhythmic death.
RESULTS

Of 2302 participants, 1524 were randomly assigned to the device group and 778 to
the control group. Participants in the device group wore the device for a median of
18.0 hours per day (interquartile range, 3.8 to 22.7). Arrhythmic death occurred in
1.6% of the participants in the device group and in 2.4% of those in the control group
(relative risk, 0.67; 95% confidence interval [CI], 0.37 to 1.21; P = 0.18). Death from
any cause occurred in 3.1% of the participants in the device group and in 4.9% of
those in the control group (relative risk, 0.64; 95% CI, 0.43 to 0.98; uncorrected
P = 0.04), and nonarrhythmic death in 1.4% and 2.2%, respectively (relative risk, 0.63;
95% CI, 0.33 to 1.19; uncorrected P = 0.15). Of the 48 participants in the device group
who died, 12 were wearing the device at the time of death. A total of 20 participants
in the device group (1.3%) received an appropriate shock, and 9 (0.6%) received an
inappropriate shock.
CONCLUSIONS

Among patients with a recent myocardial infarction and an ejection fraction of 35%
or less, the wearable cardioverter–defibrillator did not lead to a significantly lower
rate of the primary outcome of arrhythmic death than control. (Funded by the National
Institutes of Health and Zoll Medical; VEST ClinicalTrials.gov number, NCT01446965.)
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A Quick Take
is available at
NEJM.org

he incidence of sudden cardiac
death is high during the early months
after a myocardial infarction,1-3 particularly among patients with a low left ventricular
ejection fraction.2-7 Implantable cardioverter–
defibrillators (ICDs) reduce mortality among
patients with a reduced ejection fraction when
the devices are implanted months to years after
myocardial infarction.8-10 However, two randomized trials did not show a long-term mortality
benefit from ICDs that had been implanted immediately after myocardial infarction.11,12
The wearable cardioverter–defibrillator may
protect against sudden death during the immediate period after myocardial infarction, before
ICD implantation is indicated under current
guidelines (beginning 40 days after myocardial
infarction or 90 days if the patient has undergone revascularization).13,14 Registries and case
series involving high-risk patients have shown
that wearable cardioverter–defibrillators are effective in terminating ventricular tachyarrhythmias.15-19 We conducted the Vest Prevention of
Early Sudden Death Trial (VEST) — a multicenter, randomized, controlled trial — to determine the efficacy of a wearable cardioverter–
defibrillator during the period before ICDs are
indicated in patients who have had a myocardial
infarction and have a reduced ejection fraction.

Me thods

of

m e dic i n e

sively by Zoll Medical. Zoll Medical had no role
in the trial design, the selection or supervision
of trial centers, the analysis or interpretation of
the data, the preparation of the manuscript, or the
decision to submit the manuscript for publication. Zoll Medical did participate in site monitoring. The authors vouch for the completeness
and accuracy of the data and for the fidelity of
the trial to the protocol.
Participants

Patients who had been hospitalized with an acute
myocardial infarction21 and who had an ejection
fraction of 35% or less (assessed ≥8 hours after
myocardial infarction) were enrolled within 7 days
after hospital discharge. For patients who had
undergone revascularization, the ejection fraction
was assessed 8 or more hours after percutaneous
coronary intervention (PCI) or 48 or more hours
after coronary-artery bypass grafting. Patients
were excluded if they had an ICD or unipolar
pacemaker, had clinically significant valve disease, were undergoing long-term hemodialysis, or
had a chest circumference that was too small
or too large to accommodate the wearable cardioverter–defibrillator. Patients were also excluded
if they were pregnant or had been discharged to
a nursing facility with an anticipated stay of more
than 7 days. The inclusion and exclusion criteria
are provided in Table S4 in the Supplementary
Appendix. All the participants provided written
informed consent.

Trial Design and Oversight

The trial protocol (available with the full text of
this article at NEJM.org) was designed by the
investigators and originally included two components: the VEST randomized trial and the
observational Prediction of ICD Treatment Study
(PREDICTS)20; only the results of VEST are reported in this article. The protocol was approved
by the institutional review boards of the University of California, San Francisco, and the other
trial sites. Details of the history of the trial, the
role of the sponsors, and the trial oversight are
provided in Figure S1 and Tables S1, S2, and S3
in the Supplementary Appendix (available at
NEJM.org).
The trial was initially funded by the National
Institutes of Health, which appointed the members of the independent data and safety monitoring board, with additional support from Zoll
Medical. After 2011, funding was provided exclu1206
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Trial Procedures

Eligible participants were randomly assigned in a
2:1 ratio to receive a wearable cardioverter–defibrillator plus guideline-directed medical therapy
(the device group)22-27 or to receive guidelinedirected medical therapy alone (the control group)
at hospital discharge. The Zoll LifeVest wearable
cardioverter–defibrillator16-18,28,29 that was used in
this trial was commercially available in the United
States and Germany (Fig. S2 in the Supplementary Appendix). Participants in the device group
were fitted with the device, trained in its use,
and instructed to wear the device continuously
for 3 months (except while bathing). Sites were
alerted if a participant wore the device for less
than 15 hours in a 24-hour period (monitored
through the device itself). Arrhythmias that were
detected by the device were not reported to treating physicians or the trial sites unless a shock
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was delivered or cardiac arrest occurred. Per
protocol, crossovers from the control group to
the wearable cardioverter–defibrillator were not
allowed, and early ICD implantation (<3 months)
was allowed only for guideline-based secondary
prevention of sudden death.14,30,31
Follow-up and Outcomes

Participants were followed at 1 month with a
telephone call and at 3 months with an in-person
visit. At the conclusion of the trial, the National
Death Index was searched for U.S. participants
for whom vital status was unknown.
Initially, the primary outcome of the trial was
death from any cause at 60 days; however, slowerthan-expected recruitment made the originally
planned sample of 4506 patients infeasible. On
January 29, 2010, after the first 244 participants
had been enrolled, the data and safety monitoring board, the steering committee, and the institutional review boards approved a change in the
primary outcome to the combined 90-day incidence of sudden death and nonsudden death due
to ventricular tachyarrhythmia; we refer to this
outcome as arrhythmic death. The cause of death
was adjudicated by an independent panel of experts who were unaware of the group assignments (and therefore did not have any data from
the wearable cardioverter–defibrillator). With the
revised primary outcome, the sample-size target
was changed to 1890 (see the Supplementary
Appendix). In October 2015, on the basis of
lower-than-expected device wear time and without the inspection of outcome differences according to trial group32,33 (as prespecified in the
protocol), the data and safety monitoring board
recommended increasing the sample to 2300
patients.
Secondary outcomes were death from any
cause; nonarrhythmic death; hospitalization for
myocardial infarction, atrial fibrillation, congestive heart failure, stroke, or sustained ventricular
tachyarrhythmia; wearable cardioverter–defibrillator wear time (as monitored by the device); and
adverse events (Table S5 in the Supplementary
Appendix). Definitions for the adjudicated outcomes are provided in the Supplementary Appendix.

analysis, participants who had an indeterminate
cause of death were assumed not to have had
arrhythmic death but were counted in the outcome of death from any cause, and all the participants with missing vital status were assumed
to be alive. The primary outcome as well as
death from any cause, nonarrhythmic death, and
rehospitalization were compared with the use of
unadjusted log-binomial models (with relative
risks reported), with P values assessed by Pearson
chi-square tests. Time-to-event analyses were
conducted with the use of Cox models and are
reported as Kaplan–Meier plots with hazard ratios. Rare events (indeterminate cause of death
and other clinically significant arrhythmias —
nonatrial fibrillation and nonventricular tachy
arrhythmias) were analyzed with the use of exact
logistic regression. The risk of having an alarm
indicating arrhythmia was estimated with the
use of random-effects logistic models to account
for within-person clustering. P values are reported
without correction for multiple comparisons, except where noted. Additional analyses, including
sensitivity analyses to account for missing data,
survival analyses (performed with the Kaplan–
Meier method), P value corrections for multiple
comparisons, and as-treated analyses are described in the Supplementary Appendix.

R e sult s
Characteristics of the Participants

From July 2008 through April 2017, we enrolled
2348 participants at 76 sites in the United States,
at 24 in Poland, at 6 in Germany, and at 2 in
Hungary (Table S6 in the Supplementary Appendix). One U.S. site was dismissed on June 24,
2014, and the 46 participants at that site were
excluded from the analyses, owing to irregularities found by the institutional review board at
that site.
Therefore, a total of 2302 participants were
included in the analyses (1524 participants in
the device group and 778 in the control group)
(Fig. S3 in the Supplementary Appendix). The two
groups were balanced with regard to the participants’ demographic characteristics, medical
history, and characteristics of the index hospitalization for myocardial infarction (Table 1). The
Statistical Analysis
mean ejection fraction was 28%, and 83.6% of
The primary analysis was performed according the participants underwent PCI during the index
to the intention-to-treat principle. In the primary hospitalization. Table S7 in the Supplementary
n engl j med 379;13
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Table 1. Characteristics of the Participants.*
Characteristic
Age — yr
Male sex — no./total no. (%)
Body-mass index†
Race or ethnic group — no./total no. (%)‡
White
Black
Asian
Native American or Alaskan
Pacific Islander or Hawaiian
Multiple
Hispanic
Baseline condition before index hospitalization — no./total no. (%)
Current smoking
Diabetes mellitus
Hypertension
Previous myocardial infarction
Previous CABG
Previous PCI
Previous congestive heart failure
NYHA functional class
I
II
III
IV
Index hospitalization for myocardial infarction
Left ventricular ejection fraction§
Mean
Distribution — no./total no. (%)
<25%
25 to 35%
>35%
PCI during index hospitalization — no./total no. (%)
Thrombolytic agent during index hospitalization —
no./total no. (%)
CABG during index hospitalization — no. (%)
Cardiac arrest or ventricular fibrillation — no./total no. (%)
Pulmonary edema leading to intubation — no./total no. (%)
Intraaortic balloon pump — no./total no. (%)
Cardiogenic shock — no./total no. (%)
Atrial fibrillation during hospitalization — no./total no. (%)
Median maximum creatinine level (IQR) — mg/dl¶
Median no. of days from admission to randomization (IQR)

Device Group
(N = 1524)

Control Group
(N = 778)

60.9±12.6
1108/1521 (72.8)
28.4±5.5

61.4±12.3
577/772 (74.7)
28.4±5.5

1279/1491 (85.8)
143/1491 (9.6)
23/1491 (1.5)
25/1491 (1.7)
1/1491 (0.1)
20/1491 (1.3)
85/1521 (5.6)

636/751 (84.7)
75/751 (10.0)
14/751 (1.9)
12/751 (1.6)
0/751
14/751 (1.9)
34/772 (4.4)

561/1520 (36.9)
497/1521 (32.7)
994/1521 (65.4)
380/1518 (25.0)
133/1521 (8.7)
374/1520 (24.6)
247/1518 (16.3)

273/770 (35.5)
246/776 (31.7)
501/776 (64.6)
193/775 (24.9)
70/776 (9.0)
202/776 (26.0)
146/774 (18.9)

691/1520 (45.5)
529/1520 (34.8)
211/1520 (13.9)
46/1520 (3.0)

326/775 (42.1)
286/775 (36.9)
116/775 (15.0)
18/775 (2.3)

28.2±6.1

28.2±5.8

301/1519 (19.8)
1217/1519 (80.1)
1/1519 (0.1)
1275/1513 (84.3)
118/1513 (7.8)

148/777 (19.0)
627/777 (80.7)
2/777 (0.3)
650/773 (84.1)
71/773 (9.2)

14 (0.9)
169/1513 (11.2)
162/1513 (10.7)
173/1513 (11.4)
136/1513 (9.0)
156/1513 (10.3)
1.1 (0.9–1.3)
5.0 (3.0–8.0)

12 (1.5)
70/773 (9.1)
88/773 (11.4)
93/773 (12.0)
79/773 (10.2)
91/773 (11.8)
1.1 (0.9–1.4)
5.0 (3.0–7.0)

*	Plus–minus values are means ±SD. There were no significant differences (P<0.05) between the trial groups. Percent
ages may not total 100 because of rounding. CABG denotes coronary-artery bypass grafting, IQR interquartile range,
NYHA New York Heart Association, and PCI percutaneous coronary intervention.
†	The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡	Race and ethnic group were reported by the participant.
§	An ejection fraction of 35% or less was an inclusion criterion for the study. An ejection fraction of more than 35%
represents a protocol violation.
¶	To convert values for creatinine to micromoles per liter, multiply by 88.4.
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Appendix shows the baseline characteristics of
the participants who were enrolled before versus
after the protocol was amended to change the
primary outcome.
Intervention and Treatment

group wore the device for a median of 18.0 hours
per day (interquartile range, 3.8 to 22.7) and for
a mean (±SD) of 14.0±9.3 hours per day (Table 2),
with decreasing use over time. Details are provided in Figures S3 and S4 in the Supplementary
Appendix. There was no significant betweengroup difference in the rate of ICD implantation
during the follow-up period, nor was there a significant between-group difference in the timing
of or reason for implantation (Table 2, and Table
S8 in the Supplementary Appendix).

The majority of the participants in each group
received guideline-directed medical therapy for
myocardial infarction and heart failure (Table 2).
In the device group, 43 participants (2.8%) never
wore the device after randomization; in the control group, 20 participants (2.6%) received the
device outside the protocol. Including person-days Follow-up and Outcomes
in which the wearable cardioverter–defibrillator The mean follow-up was 84.3±15.6 days. A total
was not worn at all, participants in the device of 10 participants (0.7%) in the device group and
Table 2. Treatment Received during the Trial Period.*
Treatment

Device Group
(N = 1524)

Control Group
(N = 778)

P Value

1481 (97.2)

20 (2.6)

<0.001

18.0 (3.8–22.7)

0.0 (0.0–0.0)

<0.001

14.0±9.3

0.4±2.7

<0.001

Wearable cardioverter–defibrillator
Patients with device — no. (%)†
Hours per day that device was worn during follow-up‡
Median (IQR)
Mean
Implantable cardioverter–defibrillator
Patients with device — no. (%)§

67 (4.4)

44 (5.7)

0.18

62 (24–81)

58 (25–77)

0.33

Aspirin

1329 (87.2)

678 (87.1)

0.97

Other antiplatelet agent

1379 (90.5)

680 (87.4)

0.02

Statin

1386 (90.9)

696 (89.5)

0.25

Beta-blocker, including carvedilol

1411 (92.6)

720 (92.5)

0.97

ACE inhibitor or ARB

1334 (87.5)

667 (85.7)

0.23

Eplerenone or spironolactone

662 (43.4)

343 (44.1)

0.77

Other diuretic agent

736 (48.3)

385 (49.5)

0.59

Amiodarone

106 (7.0)

55 (7.1)

0.92

5 (0.3)

4 (0.5)

0.50

86 (5.6)

44 (5.7)

0.99

Median no. of days from randomization to implantation
(IQR)
Medication use — no. (%)¶

Other antiarrhythmic agent of class IA, IC, or III
Digoxin

*	P values were not corrected for multiple comparisons. ACE denotes angiotensin-converting enzyme, and ARB angio
tensin-receptor blocker .
†	The use of any wearable cardioverter–defibrillator by participants in the control group was a protocol violation.
‡	The number of hours per day that the wearable cardioverter–defibrillator was worn included follow-up days after discharge from the hospital and before death or implantable cardioverter–defibrillator (ICD) implantation and also included participants who did not wear it at all (0 hours per day on those days) in the two groups in order to describe the difference in the device coverage according to group. A total of 11 participants (4 in the device group and 7 in the control
group) who died before discharge from the hospital were excluded from this analysis.
§	The implantation of an ICD in a participant in either group before 90 days of follow-up, unless for acceptable clinical
indications for secondary prevention (e.g., cardiac arrest or sustained ventricular tachycardia during follow-up), was a
protocol violation (Table S6 in the Supplementary Appendix).
¶	Participants provided details regarding medication use at follow-up visits.
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unknown. An additional 2 participants in each
group had insufficient data to determine whether the cause of death was arrhythmic or nonarrhythmic; therefore, they were considered to
have had an indeterminate cause of death.
There was no significant difference between
the two groups in the primary outcome of ar-

of

m e dic i n e

rhythmic death (1.6% in the device group and
2.4% in the control group; relative risk, 0.67;
95% confidence interval [CI], 0.37 to 1.21;
P = 0.18) (Table 3 and Fig. 1). The total mortality
was 3.1% in the device group, as compared with
4.9% in the control group (relative risk, 0.64;
95% CI, 0.43 to 0.98; uncorrected P = 0.04). The
rate of nonarrhythmic death was 1.4% in the
device group and 2.2% in the control group

Table 3. Primary, Secondary, and Other Outcomes.*
Device Group
(N = 1524)

Control Group
(N = 778)

Relative Risk
(95% CI)

P Value

25 (1.6)

19 (2.4)

0.67 (0.37–1.21)

0.18

9

0

NA

21 (1.4)

17 (2.2)

0.63 (0.33–1.19)

2

0

NA

2 (0.1)

2 (0.3)

0.51 (0.04–7.05)

1

0

NA

48 (3.1)

38 (4.9)

0.64 (0.43–0.98)

12

0

NA

Any

475 (31.2)

253 (32.5)

0.96 (0.85–1.09)

0.51

Cardiovascular or trial-related cause

335 (22.0)

174 (22.4)

0.98 (0.84–1.16)

0.83

Recurrent myocardial infarction

53 (3.5)

32 (4.1)

0.85 (0.55–1.30)

0.44

Stroke

14 (0.9)

8 (1.0)

0.89 (0.38–2.12)

0.80
0.35

Event
Arrhythmic death
No. of patients (%)†
Device worn at time of death or event leading to death — no.
Nonarrhythmic death
No. of patients (%)‡
Device worn at time of death or event leading to death — no.

0.15

Indeterminate death
No. of patients (%)§
Device worn at time of death or event leading to death — no.

0.83

Death from any cause
No. of patients (%)
Device worn at time of death or event leading to death — no.

0.04

Rehospitalization, by cause — no. (%)¶

Congestive heart failure

87 (5.7)

52 (6.7)

0.85 (0.61–1.19)

Ventricular tachycardia or ventricular fibrillation

24 (1.6)

20 (2.6)

0.61 (0.34–1.10)

0.10

Atrial fibrillation

8 (0.5)

5 (0.6)

0.82 (0.27–2.49)

0.72

Other clinically significant arrhythmia

8 (0.5)

3 (0.4)

1.36 (0.33–8.00)

0.92

*	For common outcomes (including for the primary outcome of arrhythmic death and for other outcomes with at least five events in each
group), a simple Pearson chi-square test was used to obtain P values, and log-binomial regression was used to estimate a relative risk with
confidence intervals. For rare outcomes (<5 events in one or both groups), P values and relative risks were estimated with the use of exact
logistic regression under the assumption that odds ratios produced by logistic regression are good estimates of relative risk when the outcome is rare. P values were not corrected for multiple comparisons. Details regarding the deaths or events leading to death that occurred
while the participant was wearing the device are provided in Table S12 in the Supplementary Appendix. NA denotes not applicable.
†	The primary outcome of arrhythmic death included sudden death and nonsudden death due to ventricular tachyarrhythmia.
‡	Nonarrhythmic death included all the deaths that did not meet the criteria for either arrhythmic death or indeterminate death (see below).
§	When documentation was inadequate for characterization of deaths as arrhythmic or nonarrhythmic, they were categorized as being indeterminate. Details are provided in the Supplementary Appendix.
¶	Site investigators were instructed to report all the hospitalization events occurring during follow-up if they were for conditions related to the
heart or major arteries or to a trial procedure. These events were adjudicated for the presence of myocardial infarction, stroke, congestive heart
failure, ventricular tachycardia or ventricular fibrillation, and other clinically significant arrhythmia with the use of standard criteria (see the
Supplementary Appendix). Investigators were also asked to report the number of hospitalization events for any cause; these events were not
adjudicated.
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Figure 1. Time-to-Event Curves for the Primary
Outcome and Two Secondary Outcomes.
The primary outcome was a composite of sudden
death or death due to ventricular tachyarrhythmia
(Panel A). Secondary outcomes included nonarrhythmic
death (Panel B) and death from any cause (Panel C).
P values were not corrected for multiple comparisons.
Insets show the same data on an enlarged y axis.
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(relative risk, 0.63; 95% CI, 0.33 to 1.19; uncorrected P = 0.15). With most approaches to correction for multiple testing, the P value for the
analysis of total mortality was not significant
(Table S9 in the Supplementary Appendix).
Results from the prespecified weighted sensitivity analyses to account for participants with
unknown vital status or an indeterminate cause
of death were similar to those of the primary
analyses (Table S10 in the Supplementary Appendix). Analyses that were adjusted for the differences in length of follow-up owing to protocol changes were also similar to the main
outcome analyses (Table S11 in the Supplementary Appendix). We found no significant between-group differences in the rates of other
secondary events (Table 3).
Among the 48 participants in the device
group who died, 12 were wearing the device at
the time of death, including 9 of the 25 participants who had arrhythmic death (Table S12 in
the Supplementary Appendix). Of these 9 participants, 4 had had a ventricular tachyarrhythmia detected and had received appropriate
shocks with conversion to sinus rhythm but with
subsequent recurrent ventricular tachyarrhythmias or agonal rhythms. In the remaining participants, no tachyarrhythmias were recorded.
One other participant received an appropriate
shock and underwent ICD implantation but died
2 weeks later with ventricular tachyarrhythmia
storm. A total of 6 participants who died while
wearing the device had asystole events (>3-second pause) during death (in 2 participants, these
were preceded by multiple ventricular tachyarrhythmia episodes and shocks), which may represent terminal rhythms.
An as-treated analysis showed a rate of arrhythmic death of 0.37 per 100 person-months
of wearing the device, as compared with a rate
of 0.86 per 100 person-months of not wearing
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Table 4. Wearable Cardioverter–Defibrillator Therapies and Alarms.*
Variable

Device Group (N = 1524)

Control Group (N = 778)

P Value

no. of participants with event (%)
No. of total shocks

<0.001

0

1495 (98.1)

1

20 (1.3)

≥2

9 (0.6)

777 (99.9)
0
1 (0.1)

No. of appropriate shocks

0.008

0

1504 (98.7)

1

13 (0.9)

≥2

7 (0.5)

777 (99.9)
0
1 (0.1)

No. of inappropriate shocks

0.12

0

1515 (99.4)

778 (100)

1

7 (0.5)

0

≥2

2 (0.1)

0

No. of shocks aborted by pressing response
button†

<0.001

0

1455 (95.5)

777 (99.9)

1

43 (2.8)

1 (0.1)

2–5

11 (0.7)

0

>5

15 (1.0)

0

No. of alarms indicating arrhythmia
0

<0.001
432 (28.3)

762 (97.9)

1

115 (7.5)

1 (0.1)

2–5

252 (16.5)

2 (0.3)

6–100

579 (38.0)

12 (1.5)

>100

146 (9.6)

1 (0.1)

0

1483 (97.3)

777 (99.9)

1

22 (1.4)‡

≥2

19 (1.2)‡

No. of alarms indicating asystole

<0.001
0
1 (0.1)

*	Shown are the numbers of participants who had an event over the entire 90-day period. The wearable cardioverter–
defibrillator was used by 20 participants in the control group, who received the device outside the protocol. Percentages
may not total 100 because of rounding. P values were not corrected for multiple comparisons.
†	This analysis included arrhythmia alarms lasting more than 30 seconds that were aborted when the participant pressed
the shock-suppression button.
‡	Among 41 participants with an alarm indicating asystole, 6 events (all in the device group) were adjudicated as having
had a true asystole event.

the device (rate ratio, 0.43; 95% CI, 0.21 to 0.91;
uncorrected P = 0.03) (see the Supplementary Appendix). An as-treated analysis of total mortality
showed a rate of 0.50 per 100 person-months of
wearing the device, as compared with a rate of
1.91 per 100 person-months of not wearing the
device (rate ratio, 0.26; 95% CI, 0.14 to 0.48;
Bonferroni corrected P<0.001). Adjustment for
age, education, ejection fraction, and revascular1212
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ization had minimal effects. Potential biases in
the as-treated analyses are discussed in the
Supplementary Appendix.
Safety and Adverse Events

During a total of 1,765,772 hours of wearable
cardioverter–defibrillator wear time, participants
received 57,451 alarms for possible arrhythmias
(as determined by the device algorithms); the
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average rate (number of alarms ÷ total wear time
in hours) was 0.033 alarms per hour. With adjustment for clustering of alarms according to day
and within participant, the chance that a participant would have at least 1 arrhythmia alarm
during 24 hours of wear time was 10.8% (95%
CI, 9.8 to 11.9). Overall, accounting for crossovers
and variable time worn, arrhythmia alarms (both
false and true detections) occurred in 72% of the
participants in the device group and in 2% of
those in the control group, with 9.6% of participants in the device group being exposed to more
than 100 alarms over the 90-day period (Table 4).
The median duration of the arrhythmia alarm
was 7 seconds (interquartile range, 3 to 12).
A total of 29 participants in the device group
received at least one shock from the wearable
cardioverter–defibrillator (Table 4); 20 participants
(1.3%) received at least one appropriate shock,
and 9 (0.6%) received at least one inappropriate
shock. Of the 21 participants who received an appropriate shock (20 in the device group and 1 in
the control group), 6 died (all in the device group).
A total of 69 participants in the device group
aborted shocks by pressing the patient-response
buttons during an alarm; 3 of these participants
subsequently received appropriate shocks within
a few minutes but died, and 1 other participant
died 12 hours later, after an appropriate shock
(Table S12 in the Supplementary Appendix).
Four adverse events were potentially related to
the wearable cardioverter–defibrillator (Table S13
in the Supplementary Appendix). Three were
hospitalizations (two for aborted shocks and one
for an inappropriate shock), and one was a death
while the participant was wearing the device,
which was deemed likely to not be an arrhythmic
death (no tachyarrhythmia was recorded by the
device and emergency medical technicians noted
pulseless electrical activity on arrival).
A higher proportion of participants in the device group than in the control group reported itch
and rash (P<0.001). A lower proportion of participants in the device group than in the control
group reported shortness of breath (P = 0.004).
Details are provided in Table S14 in the Supplementary Appendix.

apy alone in patients who presented with an acute
myocardial infarction with an ejection fraction
of 35% or less. During follow-up, we observed
cardiac event rates that were similar to those in
previous studies.3,4,6,11,12 The wearable cardioverter–defibrillator did not lead to a rate of arrhythmic death during the first 90 days — the
primary outcome of the trial — that was significantly lower than the rate with guidelinedirected medical therapy alone.
The trial may have been underpowered to
detect a beneficial effect of the wearable cardioverter–defibrillator on the primary outcome. Our
power calculation anticipated a 58% lower rate
of arrhythmic death with the device than without it. The power was, in part, reduced because
5% of the deaths were adjudicated as being of
indeterminate cause and were thus removed from
the primary analysis. Misclassification of the
adjudicated cause of death may have further reduced the power for the primary outcome. It is
difficult to determine an arrhythmic cause of
death accurately for unwitnessed deaths or deaths
with limited documentation. In the Valsartan in
Acute Myocardial Infarction (VALIANT) trial,
only half the patients with sudden death who
underwent autopsy were found to have died from
arrhythmic death.34 In a recent study that used a
definition of sudden death that was similar to
the definition in our trial but that also used
autopsy as a standard for determining cause of
death, only 56% of the presumed sudden cardiac
deaths were found to be of arrhythmic origin.35
In our trial, five of nine participants with adjudicated arrhythmic death who were wearing the
device during the event had no ventricular tachy
arrhythmias (adjudicators were unaware of the
arrhythmia data from the device).
The original primary outcome of the trial was
death from any cause; for this outcome, the uncorrected P value for comparison was 0.04 in
favor of the wearable cardioverter–defibrillator.
However, this result was not corrected for multiple testing, and given the use of most such
corrections, the difference between the device
and control groups would not be significant.
Thus, the conservative interpretation is that this
result was a chance finding. As with the primary outcome, the trial may have been underDiscussion
powered to detect a beneficial effect of the deVEST compared the use of a wearable cardio- vice with regard to all-cause mortality. Although
verter–defibrillator plus guideline-directed med- there is no clear mechanism to explain a benefit
ical therapy with guideline-directed medical ther- of the wearable cardioverter–defibrillator on nonn engl j med 379;13
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arrhythmic death, it is often difficult to determine an arrhythmic cause of death, as noted
above.
As described previously,15-17 the wearable cardioverter–defibrillator was effective at converting
ventricular tachyarrhythmias, with successful
conversion in all 20 participants in the device
group who received an appropriate shock, 14 of
whom survived to 90 days (Table S12 in the
Supplementary Appendix). Nonadherence to wearing the device may have reduced the power of
the trial to show the effectiveness of this treatment strategy for the prevention of arrhythmic
death. The power calculation assumed a deviceadherence rate of 70%, a goal that was met or
exceeded in the first 2 weeks after randomization but that waned over time (Fig. S4 in the
Supplementary Appendix). It is also evident that
some patients who are successfully treated with
an appropriate shock subsequently die; not all
successful defibrillations prolong survival. However, in an as-treated analysis, a significantly
lower percentage of patients died when they
were wearing the wearable cardioverter–defibrillator than when they were not, a finding that
remained significant even after the most conservative correction for multiple comparisons. Although this result is subject to bias, it suggests
a benefit to wearing the device (see the Supplementary Appendix) and implies that low adherence to wearing the device may be a limiting
factor in the potential benefit of the wearable
cardioverter–defibrillator.
Guidelines for primary prevention of sudden
death with ICD implantation recommend waiting 40 days after an acute myocardial infarction

of

m e dic i n e

and 90 days after revascularization. Randomized
trials have shown no benefit to ICD implantation early after an acute myocardial infarction.11,12
However, mortality was high during this vulnerable period, even with guideline-directed medical therapy and revascularization. We observed
that mortality at 90 days was 4.9% in the control
group, despite 84% of the participants having
undergone PCI for acute myocardial infarction
and more than 85% being treated with guideline-directed medical therapy. It remains unclear
how to reduce the risk of arrhythmic death definitively, beyond what is possible with appropriate medical therapy, in the early period after
myocardial infarction before ICDs are indicated.
In conclusion, in this trial, we compared the
use of a wearable cardioverter–defibrillator plus
guideline-directed medical therapy with guideline-directed medical therapy alone in patients
who presented with an acute myocardial infarction with an ejection fraction of 35% or less. The
wearable cardioverter–defibrillator did not result
in a significantly lower rate of arrhythmic death
than medical therapy during the first 90 days.
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